PARP inhibitors, when used specifically in patients with BRCA gene defects, offer the possibility of attacking tumor cells and leading them to apoptosis, while in healthy cells in the same organism, the repair of single-strand breaks should continue (see Figure 3). The gene discussed is PARP1; the disease is neoplasm.